Postoperative treatment of malignant tumors of the parotid gland: radiotherapy, concomitant chemotherapy and radiation therapy?;Tumeurs malignes de la parotide : prise en charge multidisciplinaire, rôle de la radiothérapie

Cancer/Radiotherapie

Volumn 11, Issue 8, 2007, Pages 465-475

  Bouyon, A ^a   Hans, S ^a   Durdux, C ^a   Housset, M ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Concurrent radiotherapy and chemotherapy; Parotid gland cancer; Radiotherapy; Salivary neoplasms

Indexed keywords

ANTHRACYCLINE; CISPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; GEFITINIB; IMATINIB; METHOTREXATE; MITOXANTRONE; NAVELBINE; PACLITAXEL; TRASTUZUMAB;

ADENOCARCINOMA; ANATOMY; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; ECHOGRAPHY; FACIAL NERVE; HEAD AND NECK SURGERY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PAROTID GLAND CARCINOMA; PATHOLOGY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIODIAGNOSIS; SHORT SURVEY; SURGICAL ANATOMY; SURGICAL TECHNIQUE; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; TUMOR BIOPSY; ARTICLE; CANCER STAGING; FEMALE; INCIDENCE; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PAROTID GLAND TUMOR; RADIOTHERAPY; RETROSPECTIVE STUDY; SURVIVAL;

COMBINED MODALITY THERAPY; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; PAROTID NEOPLASMS; PROGNOSIS; RADIOTHERAPY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 36849036473     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2007.07.002     Document Type: Short Survey

References (39)

1. Airoldi M., Gabriele A.M., Gabriele P., Pedani F., Marchionatti S., Succo G., et al. Concomitant chemoradiotherapy followed by adjuvant chemotherapy in parotid gland undifferentiated carcinoma. Tumori 87 (2001) 14-17
2. Airoldi M., Pedani F., Succo G., Gabriele A.M., Ragona R., Marchionatti S., et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 91 (2001) 541-547
3. Armstrong J.G., Harrison L.B., Spiro R.H., Fass D.E., Strong E.W., and Fuks Z.Y. Malignant tumors of major salivary gland origin. A matched-pair analysis of the role of combined surgery and postoperative radiotherapy. Arch. Otolaryngol. Head Neck Surg. 116 (1990) 290-293
4. Armstrong J.G., Harrison L.B., Thaler H.T., Friedlander-Klar H., Fass D.E., Zelefsky M.J., et al. The indications for elective treatment of the neck in cancer of the major salivary glands. Cancer 69 (1992) 615-619
5. Badoual C., Rousseau A., Heudes D., Carnot F., Danel C., Meatchi T., et al. Evaluation of frozen section diagnosis in 721 parotid gland lesions. Histopathology 49 (2006) 538-540
6. Bensadoun R.J., Allavena C., Chauvel P., Dassonville O., Demard F., Dieu-Bosquet L., et al. Standards, Options et Recommandations 2003 pour la radiothérapie des patients atteints de tumeurs malignes des glandes salivaires (lymphomes, sarcomes et mélanomes exclus), mise à jour. Cancer Radiother. 7 (2003) 280-295
7. Bernier J. Chemoradiation in locally advanced head and neck cancer: new evidence, new challenges. Expert Rev. Anticancer Ther. 4 (2004) 335-339
8. Bragg C.M., Conway J., and Robinson M.H. The role of intensity-modulated radiotherapy in the treatment of parotid tumors. Int. J. Radiat. Oncol. Biol. Phys. 52 (2002) 729-738
9. Brizel D.M., and Esclamado R. Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. J. Clin. Oncol. 24 (2006) 2612-2617
10. Cooper J.S., and Ang K.K. Concomitant chemotherapy and radiation therapy certainly improves local control. Int. J. Radiat. Oncol. Biol. Phys. 61 (2005) 7-9
11. Cooper J.S., Pajak T.F., Forastiere A.A., Jacobs J., Campbell B.H., Saxman S.B., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 350 (2004) 1937-1944
12. Faivre S., Raymond E., Casiraghi O., Temam S., and Berthaud P. Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J. Clin. Oncol. 23 (2005) 6271-6273 (author reply 6273-4)
13. Frankenthaler R.A., Luna M.A., Lee S.S., Ang K.K., Byers R.M., Guillamondegui O.M., et al. Prognostic variables in parotid gland cancer. Arch. Otolaryngol. Head Neck Surg. 117 (1991) 1251-1256
14. Garden A.S., el-Naggar A.K., Morrison W.H., Callender D.L., Ang K.K., and Peters L.J. Postoperative radiotherapy for malignant tumors of the parotid gland. Int. J. Radiat. Oncol. Biol. Phys. 37 (1997) 79-85
15. Griffin T.W., Pajak T.F., Laramore G.E., Duncan W., Richter M.P., Hendrickson F.R., et al. Neutron vs photon irradiation of inoperable salivary gland tumors: results of an RTOG-MRC Cooperative Randomized Study. Int. J. Radiat. Oncol. Biol. Phys. 15 (1988) 1085-1090
16. Haddad R., Colevas A.D., Krane J.F., Cooper D., Glisson B., Amrein P.C., et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol. 39 (2003) 724-727
17. Halimi P., Gardner M., and Petit F. Les tumeurs des glandes salivaires. Cancer Radiother. 9 (2005) 251-260
18. Hocwald E., Korkmaz H., Yoo G.H., Adsay V., Shibuya T.Y., Abrams J., et al. Prognostic factors in major salivary gland cancer. Laryngoscope 111 (2001) 1434-1439
19. Kirkbride P., Liu F.F., O'Sullivan B., Payne D., Warde P., Gullane P., et al. Outcome of curative management of malignant tumours of the parotid gland. J. Otolaryngol. 30 (2001) 271-279
20. Koul R., Dubey A., Butler J., Cooke A.L., Abdoh A., and Nason R. Prognostic factors depicting disease-specific survival in parotid-gland tumors. Int. J. Radiat. Oncol. Biol. Phys. 68 (2007) 714-718
21. Land C.E., Saku T., Hayashi Y., Takahara O., Matsuura H., Tokuoka S., et al. Incidence of salivary gland tumors among atomic bomb survivors, 1950-1987. Evaluation of radiation-related risk. Radiat. Res. 146 (1996) 28-36
22. Laramore G.E., Krall J.M., Griffin T.W., Duncan W., Richter M.P., Saroja K.R., et al. Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council. Int. J. Radiat. Oncol. Biol. Phys. 27 (1993) 235-240
23. Laurie S.A., and Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J. Clin. Oncol. 24 (2006) 2673-2678
24. Lima R.A., Tavares M.R., Dias F.L., Kligerman J., Nascimento M.F., Barbosa M.M., et al. Clinical prognostic factors in malignant parotid gland tumors. Otolaryngol. Head Neck Surg. 133 (2005) 702-708
25. Noel G., Feuvret L., Ferrand R., and Mazeron J.J. Le traitement par neutrons : hadronthérapie partie II : bases physiques et expérience clinique. Cancer Radiother. 7 (2003) 340-352
26. Nutting C.M., Rowbottom C.G., Cosgrove V.P., Henk J.M., Dearnaley D.P., Robinson M.H., et al. Optimisation of radiotherapy for carcinoma of the parotid gland: a comparison of conventional, three-dimensional conformal, and intensity-modulated techniques. Radiother. Oncol. 60 (2001) 163-172
27. Perez C.A. 1934 Principles and practice of radiation oncology. 4th ed (2004), Lippincott Williams Wilkins, Philadelphia (c2004)
28. Pignon J.P., Bourhis J., Domenge C., and Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355 (2000) 949-955
29. Pohar S., Gay H., Rosenbaum P., Klish D., Bogart J., Sagerman R., et al. Malignant parotid tumors: presentation, clinical/pathologic prognostic factors, and treatment outcomes. Int. J. Radiat. Oncol. Biol. Phys. 61 (2005) 112-118
30. Renehan A.G., Gleave E.N., Slevin N.J., and McGurk M. Clinicopathological and treatment-related factors influencing survival in parotid cancer. Br. J. Cancer 80 (1999) 1296-1300
31. Rowbottom C.G., Nutting C.M., and Webb S. Beam-orientation optimization of intensity-modulated radiotherapy: clinical application to parotid gland tumours. Radiother. Oncol. 59 (2001) 169-177
32. Spiro R.H. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg. 8 (1986) 177-184
33. Starek I., Koranda P., Zbooil V., and Mrzena L. Sentinel lymph node biopsy in parotid gland carcinoma. Clin. Nucl. Med. 31 (2006) 203-204
34. Stennert E., Kisner D., Jungehuelsing M., Guntinas-Lichius O., Schroder U., Eckel H.E., et al. High incidence of lymph node metastasis in major salivary gland cancer. Arch. Otolaryngol. Head Neck Surg. 129 (2003) 720-723
35. Terhaard C.H., Lubsen H., Rasch C.R., Levendag P.C., Kaanders H.H., Tjho-Heslinga R.E., et al. The role of radiotherapy in the treatment of malignant salivary gland tumors. Int. J. Radiat. Oncol. Biol. Phys. 61 (2005) 103-111
36. Vander Poorten V.L., Hart A.A., van der Laan B.F., Baatenburg de Jong R.J., Manni J.J., Marres H.A., et al. Prognostic index for patients with parotid carcinoma: external validation using the nationwide 1985-1994 Dutch Head and Neck Oncology Cooperative Group database. Cancer 97 (2003) 1453-1463
37. Yaparpalvi R., Fontenla D.P., Tyerech S.K., Boselli L.R., and Beitler J.J. Parotid gland tumors: a comparison of postoperative radiotherapy techniques using three dimensional (3D) dose distributions and dose-volume histograms (DVHS). Int. J. Radiat. Oncol. Biol. Phys. 40 (1998) 43-49
38. Ying Y.L., Johnson J.T., and Myers E.N. Squamous cell carcinoma of the parotid gland. Head Neck 28 (2006) 626-632
39. Zbaren P., Schupbach J., Nuyens M., Stauffer E., Greiner R., and Hausler R. Carcinoma of the parotid gland. Am. J. Surg. 186 (2003) 57-62